Results 231 to 240 of about 139,920 (262)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Novel photonic crystal fibre for low-noise coherent supercontinuum generation. [PDF]

open access: yesSci Rep
Morel R   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy